Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Covid-19 Vaccine Effectiveness and the Test-Negative Design
Natalie E. Dean, Joseph W. Hogan, Mireille E. Schnitzer
New England Journal of Medicine (2021) Vol. 385, Iss. 15, pp. 1431-1433
Open Access | Times Cited: 155

Showing 26-50 of 155 citing articles:

Effectiveness and safety of COVID-19 vaccines on maternal and perinatal outcomes: a systematic review and meta-analysis
Silvia Fernández-García, Laura del Campo-Albendea, Dharshini Sambamoorthi, et al.
BMJ Global Health (2024) Vol. 9, Iss. 4, pp. e014247-e014247
Open Access | Times Cited: 6
A Double Machine Learning Approach for the Evaluation of COVID‐19 Vaccine Effectiveness Under the Test‐Negative Design: Analysis of Québec Administrative Data
Cong Jiang, Denis Talbot, Sara Carazo, et al.
Statistics in Medicine (2025) Vol. 44, Iss. 5
Open Access
Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine
Jennifer M. Polinski, Andrew R. Weckstein, Michael Batech, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 32
Current Challenges With the Use of Test-Negative Designs for Modeling COVID-19 Vaccination and Outcomes
Xu Shi, Kendrick Qijun Li, Bhramar Mukherjee
American Journal of Epidemiology (2022) Vol. 192, Iss. 3, pp. 328-333
Open Access | Times Cited: 23
Long-term Real-world Protection Afforded by Third mRNA Doses Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections, Coronavirus Disease 19-related Emergency Attendances and Hospitalizations Amongst Older Singaporeans During an Omicron XBB Wave
Liang En Wee, Deanette Pang, Calvin J. Chiew, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 8, pp. 1111-1119
Closed Access | Times Cited: 14
Waning of 2-Dose BNT162b2 and mRNA-1273 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Accounting for Depletion-of-Susceptibles Bias
Kristin L. Andrejko, Jake M. Pry, Jennifer F. Myers, et al.
American Journal of Epidemiology (2023) Vol. 192, Iss. 6, pp. 895-907
Open Access | Times Cited: 12
Potential Biases in Test-Negative Design Studies of COVID-19 Vaccine Effectiveness Arising from the Inclusion of Asymptomatic Individuals
Edgar Ortíz‐Brizuela, Mabel Carabalí, Cong Jiang, et al.
American Journal of Epidemiology (2024)
Open Access | Times Cited: 4
Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against Omicron in Brazil
Otávio T. Ranzani, Matt D. T. Hitchings, Rosana Leite de Melo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 21
Persistent Health Issues, Adverse Events, and Effectiveness of Vaccines during the Second Wave of COVID-19: A Cohort Study from a Tertiary Hospital in North India
Upinder Kaur, Sapna Bala, Aditi Joshi, et al.
Vaccines (2022) Vol. 10, Iss. 7, pp. 1153-1153
Open Access | Times Cited: 21
Protection against Omicron re-infection conferred by prior heterologous SARS-CoV-2 infection, with and without mRNA vaccination
Sara Carazo, Danuta M. Skowronski, Marc Brisson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 19
Bivalent mRNA vaccine effectiveness against COVID-19 among older adults in Japan: a test-negative study from the VENUS study
Yudai Tamada, Kenji Takeuchi, Taro Kusama, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Anti–SARS-CoV-2 Antibody Levels Associated With COVID-19 Protection in Outpatients Tested for SARS-CoV-2, US Flu Vaccine Effectiveness Network, October 2021–June 2022
Kelsey M. Sumner, Ruchi Yadav, Emma K. Noble, et al.
The Journal of Infectious Diseases (2024) Vol. 230, Iss. 1, pp. 45-54
Open Access | Times Cited: 3
Estimands and Estimation of COVID-19 Vaccine Effectiveness Under the Test-Negative Design
Mireille E. Schnitzer
Epidemiology (2022) Vol. 33, Iss. 3, pp. 325-333
Open Access | Times Cited: 18
COVID-19 Vaccines against Omicron Variant: Real-World Data on Effectiveness
Yousra Kherabi, Odile Launay, Liêm Binh Luong Nguyen
Viruses (2022) Vol. 14, Iss. 10, pp. 2086-2086
Open Access | Times Cited: 18
Estimated Impact of the US COVID-19 Vaccination Campaign—Getting to 94% of Deaths Prevented
Malia Jones, Karim Khader, Westyn Branch‐Elliman
JAMA Network Open (2022) Vol. 5, Iss. 7, pp. e2220391-e2220391
Open Access | Times Cited: 17
Frailty Reduces Vaccine Effectiveness Against SARS-CoV-2 Infection: A Test-Negative Case Control Study Using National VA Data
Fei Tang, Iriana S Hammel, Melissa K. Andrew, et al.
The journal of nutrition health & aging (2023) Vol. 27, Iss. 2, pp. 81-88
Open Access | Times Cited: 9
Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants
Katia Bruxvoort, Lina S. Sy, Lei Qian, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 22
Vaccine effectiveness and duration of protection against symptomatic infections and severe Covid-19 outcomes in adults aged 50 years and over, France, January to mid-December 2021
Milena Suarez Castillo, Hamid Khaoua, Noémie Courtejoie
Global Epidemiology (2022) Vol. 4, pp. 100076-100076
Open Access | Times Cited: 14
Dynamics of Naturally Acquired Immunity Against Severe Acute Respiratory Syndrome Coronavirus 2 in Children and Adolescents
Tal Patalon, Yaki Saciuk, Galit Perez, et al.
The Journal of Pediatrics (2023) Vol. 257, pp. 113371-113371
Open Access | Times Cited: 8
Estimated COVID-19 vaccine effectiveness against seroconversion from SARS-CoV-2 Infection, March–October, 2021
Ian D. Plumb, Lida M. Fette, Ashley H. Tjaden, et al.
Vaccine (2023) Vol. 41, Iss. 15, pp. 2596-2604
Open Access | Times Cited: 8
Protection of homologous and heterologous boosters after primary schemes of rAd26-rAd5, ChAdOx1 nCoV-19 and BBIBP-CorV during the omicron outbreak in adults of 50 years and older in Argentina: a test-negative case–control study
Soledad González, Santiago Olszevicki, Alejandra Gaiano, et al.
The Lancet Regional Health - Americas (2023) Vol. 27, pp. 100607-100607
Open Access | Times Cited: 8
Declining Levels of Neutralizing Antibodies to SARS-CoV-2 Omicron Variants Are Enhanced by Hybrid Immunity and Original/Omicron Bivalent Vaccination
Sharon Walmsley, Majid Nabipoor, Freda Qi, et al.
Vaccines (2024) Vol. 12, Iss. 6, pp. 564-564
Open Access | Times Cited: 2
A Shot in the Arm for Vaccination Intention: The Media and the Health Belief Model in Three Chinese Societies
Ruoheng Liu, Yi‐Hui Christine Huang, Jie Sun, et al.
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 6, pp. 3705-3705
Open Access | Times Cited: 13
COVID-19 vaccination effectiveness rates by week and sources of bias: a retrospective cohort study
Anna Ostropolets, George Hripcsak
BMJ Open (2022) Vol. 12, Iss. 8, pp. e061126-e061126
Open Access | Times Cited: 13
Comparative Magnitude and Persistence of Humoral SARS-CoV-2 Vaccination Responses in the Adult Population in Germany
Alex Dulovic, Barbora Kessel, Manuela Harries, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 12

Scroll to top